Psoriasis, Atopic dermatitis
Conditions
Interventions
For cohort-1, male and female Caucasian subjects will receive single oral dose administration of SCD-044 at a dose of 2 mg under fasting conditions.
Cohort-2 consist of three periods. Male Japanase su
Sponsors
Toida Tsuneyuki
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - Adult males aged between18 and 50 years with body mass index (BMI) between 18 and 28 kg/m2. - Adult females (non-pregnant, non-lactating) aged between 18 and 50 years with BMI between 18 and 28 kg/m2. - (only for cohort 1) Subjects of Caucasian descent as defined by 1) having 2 parents and 4 grandparents of Caucasian including White and Hispanic ethnicities, and 2) maintaining a Western lifestyle. - (only for cohort 2) Subjects of native Japanese descent as defined by 1) having 2 parents and 4 grandparents of Japanese descent, 2) not residing outside of Japan for >=10 years, and 3) maintaining a Japanese lifestyle.
Exclusion criteria
Exclusion criteria: - History or presence of clinically relevant, hepatic, neurological, pulmonary, ophthalmological, endocrine, psychiatric, or other systemic disease or history of any major surgical conditions within 4 weeks prior to the screening condition consider to that may affect compromise subject safety or interfere with the evaluation of the safety based on the judgment of the investigator. No Surgery is to be planned during the length of the study. - At screening the subject has any conditions or treatments that may affect cardiovascular function. - History of macular edema or diagnosed before administration of study drug will be excluded. - History or presence of uveitis or are currently complicated. - Any subjects the investigator considers ineligible.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| AUC0-inf and Cmax of SCD-044 | — |
Contacts
Public ContactTomoe Yamanaka
Sun Pharma Japan Limited
Outcome results
None listed